March, 2024
March 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Amalya Sargsyan: Is it time to consider SBRT plus SOC as the new standard in managing oligoprogressive NSCLC?
Jan 21, 2024, 07:38

Amalya Sargsyan: Is it time to consider SBRT plus SOC as the new standard in managing oligoprogressive NSCLC?

Amalya Sargsyan, Medical Oncologist at the

Narek Shaverdian, among other experts, shared new promising data from phase II study on the role of Stereotactic body radiation therapy (SBRT) addition to standard of care (SOC) for Non-small cell lung cancer (NSCLC) and Breast c-r oligoprogression.

  • SBRT shows promise as an addition to SOC in NSCLC, offering a fourfold increase in PFS. SBRT plus SOC group showed Progression-free survival (PFS) of 10.0 months versus 2.2 months in SOC-only group (HR 0.41, 95%CI 0.22-0.75; p=0.0039)
  • No significant PFS difference with SBRT plus SOC for breast cancer.

Is it time to consider SBRT plus SOC as the new standard in managing oligoprogressive NSCLC? Make sure to read the full article for more details.”

Source: Amalya Sargsyan/LinkedIn